ClinicalTrials.gg
RecruitingNCT01915511IPF/ILD-PROUpdated Nov 12, 2026

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

An observational study in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, sponsored by Duke University. Recruiting at 50 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Duke University · Observational

How we know

From the registry’s dates

  • Started Jun 2014; still recruiting 12 years 5 months later.
Updated Nov 12, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Planned enrollment
5th of 45
3,000 · median 320
Started
2014
with 2 others
Observational
46 of 236
13 open now
Primary completion
2028-01
later than 29 of 50 live
Registered
75th of 236
by date
Lead sponsor
7 of 236
Duke University

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 5th largest by planned enrollment of the 45 observational ones that give a count, is one of 3 that started in 2014, is one of 46 observational ones, reaches primary completion later than 29 of the 50 other live ones, and was the 75th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Read the detailed description

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease

Keywords

  • Idiopathic pulmonary fibrosis
  • Pulmonary fibrosis
  • IPF
  • Registry
  • 1199.174
  • Interstitial Lung Disease
  • ILD
  • Interstitial Lung Disease with Progressive Phenotype
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide
  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.
  • Age 21 years or older, or
  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung .
    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - \<10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - \<10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion criteria

Exclusion Criteria:

  • , treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Subjects with a new IPF diagnosis

    Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

  • Subjects with a non-IPF ILD diagnosis

    Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

  • New Subjects with a new IPF diagnosis

    Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

06

What researchers measure

Primary outcomes

  1. Data on natural history of IPF & non-IPF chronic fibrosing ILD

    Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

    Time frame: End of Study (3 years after last patient will be enrolled)

  2. Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

    Understand the current practice patterns for diagnosis of IPF \& non-IPF chronic fibrosing ILD

    Time frame: End of Study (3 years after last patient will be enrolled)

  3. Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.

    Describe the impact of IPF \& non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

    Time frame: End of Study (3 years after last patient will be enrolled)

  4. Blood samples for future research.

    Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

    Time frame: End of Study (3 years after last patient will be enrolled)

  5. HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)

    Collect longitudinal HRCT images for future research

    Time frame: End of Study (3 years after last patient will be enrolled)

Secondary outcomes

  1. Data on management practices compared to existing guidelines.

    Compare disease-specific management practices with existing guidelines.

    Time frame: End of Study (3 years after last patient will be enrolled)

  2. Data on center-specific practices on outcomes.

    Determine the influence of center-specific practices on patient outcomes.

    Time frame: End of Study (3 years after last patient will be enrolled)

07

Study locations

42 of 50 sites recruiting
08

References and documents

Publications

  • MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print. PubMed 42730644 ↗
  • Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec. PubMed 42548385 ↗
  • Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x. PubMed 42201372 ↗
  • Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2. PubMed 41882705 ↗
  • Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5. PubMed 41126189 ↗
  • Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6. PubMed 40022059 ↗
  • Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26. PubMed 40020995 ↗
  • Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC. PubMed 39531618 ↗
  • Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6. PubMed 39443991 ↗
  • Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8. PubMed 39334205 ↗
  • Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7. PubMed 38273290 ↗
  • Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5. PubMed 37612608 ↗
  • Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0. PubMed 37344825 ↗
  • Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC. PubMed 35073248 ↗
  • Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7. PubMed 34997268 ↗
  • de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7. PubMed 34996465 ↗
  • Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4. PubMed 34592998 ↗
  • Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC. PubMed 32574517 ↗
  • Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29. PubMed 32004554 ↗
  • O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15. PubMed 31954102 ↗
  • Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z. PubMed 31640794 ↗
  • Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9. PubMed 31142314 ↗
  • O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016. PubMed 26835134 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2014 (actual). Primary completion is estimated for Jan 2028, 163 months after the start.

Of 74 non-industry observational studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 102. This study's planned 163 months is above that.

Counting every sponsor, half of 88 studies reached it within 51 months; a quarter within 29 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2013
First posted
Aug 5, 2013
StartActual
Jun 2014
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed. PMG Research is now Terminated
Show 4 added (4 United States)
  • University of Kentucky · Lexington, United States
  • Penn State College of Medicine - Hershey · Hershey, United States
  • Intermountain Health · Salt Lake City, United States
  • Inova Health Care Services · Falls Church, United States
Show 1 removed
  • Inova · Falls Church, United States
Nov 12, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42730644 ↗
Nov 12, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • University of South Florida · Tampa, United StatesContact a•••@tgh.org · •••6955→n•••@tgh.org
  • Cleveland Clinic · Cleveland, United StatesContact person changed (no phone or email listed)
  • University of Texas Southwestern · Dallas, United StatesContact M•••@utsouthwestern.edu · •••1295→M•••@utsouthwestern.edu · •••6489
  • Baylor University Medical Center at Dallas · Dallas, United StatesContact K•••@bswhealth.org · •••2570→M•••@bswhealth.org · •••6276
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42730644 ↗
    4 sites added, 1 site removed. PMG Research is now Terminated
    Show 4 added (4 United States)
    • University of Kentucky · Lexington, United States
    • Penn State College of Medicine - Hershey · Hershey, United States
    • Intermountain Health · Salt Lake City, United States
    • Inova Health Care Services · Falls Church, United States
    Show 1 removed
    • Inova · Falls Church, United States
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • University of South Florida · Tampa, United StatesContact a•••@tgh.org · •••6955→n•••@tgh.org
    • Cleveland Clinic · Cleveland, United StatesContact person changed (no phone or email listed)
    • University of Texas Southwestern · Dallas, United StatesContact M•••@utsouthwestern.edu · •••1295→M•••@utsouthwestern.edu · •••6489
    • Baylor University Medical Center at Dallas · Dallas, United StatesContact K•••@bswhealth.org · •••2570→M•••@bswhealth.org · •••6276

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01915511
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Aug 5, 2013
Start date
Jun 2014
Primary completion
Jan 2028 (estimated)
Completion
Jan 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Rosalia Blanco
Contact
rosalia.blanco@duke.edu
919-660-0890
Scott Palmer, MD
principal investigator · Duke Clinical Research Institute, Duke University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion